General
Preferred name
FOSTEMSAVIR
Synonyms
BMS-663068 Tris ()
BMS-663068 ()
Fostemsavir Tris ()
BMS-663068 (Tris) ()
BMS-663068, Rukobia ()
FOSTEMSAVIR TROMETHAMINE ()
Bms-663068 free acid ()
BMS-663068 TROMETHAMINE ()
BMS-663068-03 ()
GSK3684934A ()
GSK-3684934A ()
Rukobia ()
Fostemsavir trometamol ()
BMS 663068 ()
P&D ID
PD058977
CAS
864953-29-7
864953-39-9
Tags
available
prodrug
drug
Approved by
EMA
FDA
First approval
2020
Drug indication
HIV infection
Human immunodeficiency virus infection
HIV-1 infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Fostemsavir is a phosphonooxymethyl prodrug of temsavir (BMS-626529) . It is classified as an attachment inhibitor . Temsavir binds to HIV envelope glycoprotein 120 (gp120) and thereby blocks viral attachment to the host CD4 molecule on T-lymphocytes. Naturally ocurring HIV-1 gp120 polymorphisms that could impart resistance to fostemsavir are uncommon . (GtoPdb)
DESCRIPTION Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.
PRICE 192
DESCRIPTION Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl proagent of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.
PRICE 211
DESCRIPTION Fostemsavir (BMS-663068) is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection. (TargetMol Bioactive Compound Library)
DESCRIPTION BMS-663068 tris is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection. (BOC Sciences Bioactive Compounds)
DESCRIPTION Fostemsavir Tris (BMS-663068 Tris) is the prodrug of BMS-626529,is a oral, safe and effective inhibitor of HIV-1 attachment. It inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells. (TargetMol Bioactive Compound Library)
Compound Sets
19
AdooQ Bioactive Compound Library
A15025
A15026
BOC Sciences Bioactive Compounds
bms-663068-tris-cas-864953-39-9-item-84-463660
Cayman Chemical Bioactives
37708
ChEMBL Approved Drugs
CHEMBL3301594
CHEMBL3301598
ChEMBL Drugs
CHEMBL3301594
CHEMBL3301598
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB11796
DrugBank Approved Drugs
DB11796
DrugCentral
5401
DrugCentral Approved Drugs
5401
DrugMAP
DM50ILT
DrugMAP Approved Drugs
DM50ILT
Guide to Pharmacology
11100
MedChem Express Bioactive Compound Library
HY-15440A
HY-15440B
NCATS Inxight Approved Drugs
97IQ273H4L
ReFrame library
Selleckchem Bioactive Compound Library
bms-663068
TargetMol Bioactive Compound Library
T3523
T10570
External IDs
39
Properties
(calculated by RDKit )
Molecular Weight
583.16
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
5
Aromatic Ring Count
4
cLogP
1.17
TPSA
182.21
Fraction CSP3
0.28
Chiral centers
0.0
Largest ring
6.0
QED
0.17
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
HIV-1
gp120/CD4
MOA
Antiviral
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Solubility
In Vitro:<br/>DMSO : 125 mg/mL(177.40 mM
Need ultrasonic)<br/>H2O : 100 mg/mL(141.92 mM
Need ultrasonic)<br/>In Vivo:<br/>1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline<br/>Solubility: ≥ 2.08 mg/mL (2.95 mM)
Clear solution<br/>2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline)<br/>Solubility: ≥ 2.08 mg/mL (2.95 mM)
Clear solution<br/>3.Add each solvent one by one:10% DMSO >> 90%corn oil<br/>Solubility: ≥ 2.08 mg/mL (2.95 mM)
Clear solution
Source data